What should the Lantus (insulin glargine) dose, carb coverage, and correction scale be for a 49-year-old male with type 2 diabetes, previously on Metformin (metformin hydrochloride), with a history of Diabetic Ketoacidosis (DKA) and current Hyperglycemia (A1C 12.3%)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Insulin Dosing for Post-DKA Type 2 Diabetes with Severe Hyperglycemia

Start Lantus at 33 units daily (0.5 units/kg/day), use a carbohydrate ratio of 1:10 for meal coverage with rapid-acting insulin, and apply a correction scale of 1 unit per 30 mg/dL above 150 mg/dL. 1, 2, 3

Basal Insulin (Lantus) Dosing

Begin with 0.5 units/kg/day of insulin glargine (Lantus), which equals approximately 33 units daily for this 66 kg patient. 2, 3 This conservative starting dose is appropriate given:

  • Recent DKA resolution requiring careful monitoring 2
  • A1C of 12.3% indicating severe hyperglycemia requiring combination basal-bolus therapy 1, 3
  • Normal renal function (Cr 0.35) allowing standard dosing 4

The American Diabetes Association recommends that patients presenting with ketoacidosis initially require insulin therapy, with subsequent addition of metformin after metabolic stabilization. 2 Given the DKA has now resolved and the patient is eating well, you should restart metformin (titrating to 2000 mg daily) while continuing insulin therapy. 2

Carbohydrate Coverage (Bolus Insulin)

Use a carbohydrate ratio of 1:10 (1 unit of rapid-acting insulin per 10 grams of carbohydrate) for meal coverage. 1, 3

  • Calculate the remaining 50% of total daily insulin dose (approximately 33 units) to be divided among three meals 3
  • This translates to roughly 11 units per meal if eating consistently, adjusted based on actual carbohydrate intake 3
  • Use rapid-acting insulin (lispro, aspart, or glulisine) given 0-15 minutes before meals 5

Correction Scale

Apply a correction factor of 1 unit per 30 mg/dL above target of 150 mg/dL. 1, 3 This is calculated using the "1800 rule" divided by total daily dose:

  • 1800 ÷ 66 units = approximately 27-30 mg/dL per unit 3
  • Check blood glucose at least 4 times daily (fasting and before each meal) 1, 3
  • Add correction insulin to carbohydrate coverage doses 3

Critical Monitoring and Titration

Titrate basal insulin by 10-30% every 2-3 days based on fasting glucose values, targeting 100-130 mg/dL fasting. 2, 3

  • Monitor blood glucose at least 4 times daily during the titration phase 1, 3
  • Consider continuous glucose monitoring to prevent DKA recurrence given his history 1
  • Recheck A1C in 3 months to assess treatment effectiveness 3

DKA Prevention Education

This patient requires specific sick day management education given his recent DKA. 1, 3

  • Never stop insulin during illness, even when not eating 1, 3
  • Check urine or blood ketones when glucose exceeds 200 mg/dL, during illness, or when insulin doses are missed 1
  • Maintain hydration with non-caloric fluids during illness 1, 3
  • Provide supplemental rapid-acting insulin based on blood glucose readings during illness 1
  • Watch for Kussmaul respiration (deep, rapid breathing) as a sign of developing acidosis 1

Common Pitfalls to Avoid

  • Do not stop metformin abruptly - restart it after DKA resolution and continue during insulin titration, as the combination reduces weight gain and insulin requirements compared to insulin alone 2, 5
  • Do not use correction insulin alone without basal coverage - basal-bolus regimens have superior outcomes compared to sliding scale alone in preventing complications 4
  • Avoid undertitration - 40% of patients starting insulin remain above A1C 8% due to inadequate dose escalation; be aggressive with titration 6
  • Send pancreatic autoantibodies (GAD, IA-2, ZnT8) to confirm this is truly type 2 diabetes and not late-onset type 1, as this affects long-term management 2

References

Guideline

Management of Severe Hyperglycemia and Prevention of Diabetic Ketoacidosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Initial Treatment of Ketosis-Prone Diabetes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Severe Hyperglycemia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

EADSG Guidelines: Insulin Therapy in Diabetes.

Diabetes therapy : research, treatment and education of diabetes and related disorders, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.